| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
|
Lancet
|
2007
|
20.57
|
|
2
|
Transcatheter versus surgical aortic-valve replacement in high-risk patients.
|
N Engl J Med
|
2011
|
15.70
|
|
3
|
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
|
BMJ
|
2007
|
14.52
|
|
4
|
Eplerenone in patients with systolic heart failure and mild symptoms.
|
N Engl J Med
|
2010
|
14.43
|
|
5
|
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
|
J Clin Epidemiol
|
2008
|
14.36
|
|
6
|
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.
|
JAMA
|
2006
|
11.87
|
|
7
|
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.
|
PLoS Med
|
2007
|
10.43
|
|
8
|
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
|
Ann Intern Med
|
2007
|
8.77
|
|
9
|
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
|
Lancet
|
2009
|
8.54
|
|
10
|
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
|
PLoS Med
|
2007
|
8.46
|
|
11
|
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.
|
Ann Intern Med
|
2007
|
7.87
|
|
12
|
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
|
N Engl J Med
|
2007
|
7.86
|
|
13
|
A factorial trial of six interventions for the prevention of postoperative nausea and vomiting.
|
N Engl J Med
|
2004
|
7.08
|
|
14
|
Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials.
|
Lancet
|
2009
|
6.82
|
|
15
|
Bivalirudin during primary PCI in acute myocardial infarction.
|
N Engl J Med
|
2008
|
5.86
|
|
16
|
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.
|
Epidemiology
|
2007
|
5.77
|
|
17
|
Bivalirudin for patients with acute coronary syndromes.
|
N Engl J Med
|
2006
|
5.49
|
|
18
|
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
|
Bull World Health Organ
|
2007
|
5.38
|
|
19
|
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
|
N Engl J Med
|
2007
|
5.37
|
|
20
|
Ferric carboxymaltose in patients with heart failure and iron deficiency.
|
N Engl J Med
|
2009
|
5.34
|
|
21
|
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
|
Epidemiology
|
2007
|
5.12
|
|
22
|
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
|
Diabetes Care
|
2006
|
5.05
|
|
23
|
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.
|
J Am Coll Cardiol
|
2007
|
4.74
|
|
24
|
Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.
|
JAMA
|
2012
|
4.73
|
|
25
|
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
|
Prev Med
|
2007
|
4.29
|
|
26
|
Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials.
|
JAMA
|
2012
|
4.13
|
|
27
|
Strategy for intention to treat analysis in randomised trials with missing outcome data.
|
BMJ
|
2011
|
4.12
|
|
28
|
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.
|
N Engl J Med
|
2015
|
3.81
|
|
29
|
Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis.
|
J Am Coll Cardiol
|
2004
|
3.67
|
|
30
|
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial.
|
Lancet
|
2004
|
3.40
|
|
31
|
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
|
JAMA
|
2007
|
3.07
|
|
32
|
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.
|
Lancet
|
2011
|
3.00
|
|
33
|
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
|
JAMA
|
2007
|
2.90
|
|
34
|
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
|
Lancet
|
2009
|
2.82
|
|
35
|
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.
|
Eur Heart J
|
2010
|
2.68
|
|
36
|
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
|
Lancet
|
2007
|
2.67
|
|
37
|
A risk score to predict bleeding in patients with acute coronary syndromes.
|
J Am Coll Cardiol
|
2010
|
2.62
|
|
38
|
Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy.
|
J Am Coll Cardiol
|
2003
|
2.54
|
|
39
|
Adaptive increase in sample size when interim results are promising: a practical guide with examples.
|
Stat Med
|
2010
|
2.49
|
|
40
|
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
|
Circulation
|
2007
|
2.41
|
|
41
|
Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data.
|
J Am Coll Cardiol
|
2010
|
2.17
|
|
42
|
[The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies].
|
Gac Sanit
|
2008
|
1.87
|
|
43
|
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.86
|
|
44
|
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
|
JAMA
|
2007
|
1.84
|
|
45
|
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
|
J Am Coll Cardiol
|
2013
|
1.83
|
|
46
|
Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
|
N Engl J Med
|
2009
|
1.72
|
|
47
|
When (not) to stop a clinical trial for benefit.
|
JAMA
|
2005
|
1.69
|
|
48
|
Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trials.
|
Heart
|
2011
|
1.55
|
|
49
|
Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients.
|
BMJ
|
2005
|
1.49
|
|
50
|
The effect of age on outcomes of coronary artery bypass surgery compared with balloon angioplasty or bare-metal stent implantation among patients with multivessel coronary disease. A collaborative analysis of individual patient data from 10 randomized trials.
|
J Am Coll Cardiol
|
2012
|
1.46
|
|
51
|
Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials (FIR).
|
Circulation
|
2011
|
1.40
|
|
52
|
Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.
|
Eur Heart J
|
2007
|
1.37
|
|
53
|
[The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies].
|
Rev Esp Salud Publica
|
2008
|
1.35
|
|
54
|
Sharing Data from Cardiovascular Clinical Trials - A Proposal.
|
N Engl J Med
|
2016
|
1.34
|
|
55
|
Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3).
|
J Am Coll Cardiol
|
2005
|
1.31
|
|
56
|
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
|
Pulm Pharmacol Ther
|
2010
|
1.30
|
|
57
|
Impact of missing data due to selective dropouts in cohort studies and clinical trials.
|
Epidemiology
|
2002
|
1.30
|
|
58
|
Categorisation of continuous risk factors in epidemiological publications: a survey of current practice.
|
Epidemiol Perspect Innov
|
2010
|
1.28
|
|
59
|
Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial.
|
Eur Heart J
|
2009
|
1.21
|
|
60
|
Randomized trials, statistics, and clinical inference.
|
J Am Coll Cardiol
|
2010
|
1.15
|
|
61
|
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations.
|
Circulation
|
2012
|
1.06
|
|
62
|
[Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration].
|
Gac Sanit
|
2009
|
1.05
|
|
63
|
Safety of drug-eluting stents: demystifying network meta-analysis.
|
Lancet
|
2007
|
1.04
|
|
64
|
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.
|
Eur J Heart Fail
|
2013
|
1.04
|
|
65
|
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme.
|
Eur J Heart Fail
|
2010
|
1.00
|
|
66
|
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).
|
Cardiovasc Diabetol
|
2008
|
0.99
|
|
67
|
More on subgroup analyses in clinical trials.
|
N Engl J Med
|
2008
|
0.96
|
|
68
|
An international multicenter protocol to assess the single and combined benefits of antiemetic interventions in a controlled clinical trial of a 2x2x2x2x2x2 factorial design (IMPACT).
|
Control Clin Trials
|
2003
|
0.96
|
|
69
|
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved.
|
Eur J Heart Fail
|
2013
|
0.96
|
|
70
|
Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions.
|
Am J Cardiol
|
2004
|
0.95
|
|
71
|
When to stop a clinical trial early for benefit: lessons learned and future approaches.
|
Circ Heart Fail
|
2012
|
0.95
|
|
72
|
Learning from recent trials and shaping the future of acute heart failure trials.
|
Am Heart J
|
2013
|
0.92
|
|
73
|
Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2008
|
0.92
|
|
74
|
Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial.
|
Am Heart J
|
2012
|
0.91
|
|
75
|
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
|
Am Heart J
|
2011
|
0.90
|
|
76
|
Eliciting and using expert opinions about influence of patient characteristics on treatment effects: a Bayesian analysis of the CHARM trials.
|
Stat Med
|
2005
|
0.88
|
|
77
|
Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials.
|
JACC Cardiovasc Interv
|
2012
|
0.87
|
|
78
|
Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy.
|
JACC Cardiovasc Interv
|
2009
|
0.86
|
|
79
|
Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial).
|
Am J Cardiol
|
2011
|
0.84
|
|
80
|
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study.
|
Diabetes Care
|
2011
|
0.83
|
|
81
|
Adjusting treatment comparisons to account for non-randomized interventions: an example from an angina trial.
|
Stat Med
|
2003
|
0.83
|
|
82
|
The effect of internal thoracic artery grafts on long-term clinical outcomes after coronary bypass surgery.
|
J Thorac Cardiovasc Surg
|
2011
|
0.83
|
|
83
|
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
|
Eur Heart J
|
2012
|
0.83
|
|
84
|
Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
|
Eur J Heart Fail
|
2012
|
0.82
|
|
85
|
Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials).
|
Am J Cardiol
|
2011
|
0.81
|
|
86
|
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
|
Eur J Heart Fail
|
2007
|
0.80
|
|
87
|
Ethical dilemmas and malfunctions in clinical trials research.
|
Ann Intern Med
|
2012
|
0.79
|
|
88
|
The science of risk models.
|
Eur J Prev Cardiol
|
2012
|
0.79
|
|
89
|
Quality management of a large randomized double-blind multi-centre trial: the ACTION experience.
|
Contemp Clin Trials
|
2007
|
0.78
|
|
90
|
Costs of an early intervention versus a conservative strategy in acute coronary syndrome.
|
Int J Cardiol
|
2007
|
0.78
|
|
91
|
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
|
Eur Heart J
|
2013
|
0.78
|
|
92
|
Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial.
|
EuroIntervention
|
2016
|
0.77
|
|
93
|
Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy.
|
Eur Heart J
|
2013
|
0.76
|
|
94
|
Reply: Do the 10-Year Mortality Outcomes of RITA-3 Inform Contemporary Clinical Practice?
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
95
|
Reply: Survival Differences in Clinical Trials With Long-Term Follow-up.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
96
|
Reporting noninferiority trials--reply.
|
JAMA
|
2013
|
0.75
|
|
97
|
Reply: Last Nail in the Coffin for Propensity Scores in Observational Cardiovascular Studies?
|
J Am Coll Cardiol
|
2017
|
0.75
|
|
98
|
Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy).
|
Am J Cardiol
|
2010
|
0.75
|